About

Jeffrey A. Chodakewitz, M.D. has served as a member of our board of directors since August 2018. Dr. Chodakewitz has decades of experience holding leadership positions in multiple drug development organizations. Most recently, Dr. Chodakewitz served as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals. Prior to that role, Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs at Vertex from November 2014 to April 2018 and was a member of the Vertex Executive Committee. Prior to joining Vertex in 2014, he spent over 20 years at Merck & Co., where he served in a number of positions including Head of Infectious Diseases and Vaccines Global Development, Senior Vice President of Global Scientific Strategy (Infectious Disease, Respiratory & Immunology) and Senior Vice President of Late Stage Development. Prior to Merck, he served in academic positions at Yale University School of Medicine and New York University’s Bellevue Medical Center. Dr. Chodakewitz currently serves on the board of Tetraphase Pharmaceuticals, Inc. (TTPH). He holds a B.S in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine.

Paul Fonteyne has served as a member of our board of directors since December 2017. Mr. Fonteyne most recently served as the Chairman of Boehringer Ingelheim USA Corporation (BI USA), and President, Animal Health for BI USA from March 2018 through December 2018. Prior to that role, Mr. Fonteyne served as the United States Country Managing Director and President and Chief Executive Officer of BI USA from November 2011 through March 2018. Previously, Mr. Fonteyne served as Senior Corporate Vice President in Boehringer Ingelheim GmbH from January 2009 to September 2011. From November 2003 to December 2008 he served as Executive Vice President, Head of Marketing and Sales for Prescription Medicines at Boehringer-Ingelheim Pharmaceuticals, Inc. Mr. Fonteyne currently serves on the board of directors of AMAG Pharmacueticals, Inc. (AMAG) and on the advisory board of the Brigham and Women’s Hospital Lung Center and the board of PhRMA (the leading pharmaceutical industry association). Mr. Fonteyne received his MBA from Carnegie-Mellon University and his MS in Chemical Engineering from the Polytechnic School at the University of Brussels.

Michael Grissinger has served as a member of our board of directors since November 2018. Mr. Grissinger has decades of experience in business development and licensing leadership roles at global pharmaceutical companies.  He recently retired from Johnson & Johnson, Inc. in April 2018 after a 25-year career beginning in January 1996. During his tenure at Johnson & Johnson, Mr. Grissinger held various positions including Vice President Mergers and Acquisitions Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018, Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016, Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the board of Akari Therapeutics, Plc (AKTX). Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.

Mr. Schor is Co-Founder, President and Chief Executive Officer of resTORbio. Mr. Schor has led biotech companies across all stages, from formation, building a team and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL). Mr. Schor served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and at leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds a M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

Jonathan Silverstein has served as a member of our board of directors since November 2017. Mr. Silverstein is currently a general partner at OrbiMed, a healthcare investment firm, where he has worked since December 1998. Previously, Mr. Silverstein was a director of life sciences in the investment banking department at Sumitomo Bank. Mr. Silverstein currently serves on the board of directors of Avedro Inc. (AVDR) and Arcutis Biotherapeutics, Inc. (ARQT), as well as on the boards of directors of several private companies. Mr. Silverstein holds a B.A. from Denison University and a J.D. and M.B.A. from the University of San Diego.

David Steinberg has served as a member of our board of directors since March 2017. Mr. Steinberg is currently a general partner at Longwood Fund, which he joined in September 2018. Mr. Steinberg is a co-founder of PureTech Health plc (PRTC.L) and served as the Chief Innovation Officer from September 2002 through August 2018. As a senior executive officer of PureTech Health, Mr. Steinberg was involved in initiating and leading multiple PureTech Health programs, including PureTech Health’s microbiome initiative, lymphatic biology platform and immune-oncology pipeline. Previously, Mr. Steinberg was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology clients. Mr. Steinberg is also a member of the University of Chicago Tech Innovation Fund Advisory Committee. Mr. Steinberg is the founder and former Chief Executive Officer of Pyxis Oncology, Inc. and currently serves on its board of directors. He received his B.A. in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Booth School of Business with an M.B.A. in Strategy and Finance.

LLynne Sullivan has served as a member of our board of directors since December 2017. Ms. Sullivan retired from Compass Therapeutics, LLC in August 2019, where she had worked as Chief Financial Officer since December 2018. Previously, Ms. Sullivan served as Senior Vice President of Finance for Biogen Inc. from September 2016 through December 2018. Prior to that position, Ms. Sullivan served as Senior Vice President, Tax and Corporate Finance from June 2015 through December 2018. Ms. Sullivan also served as Vice President, Tax from April 2008 through June 2015. At Biogen Inc., Ms. Sullivan had global responsibility for Biogen’s Financial Planning & Analysis, Corporate Tax, and Corporate Finance groups, which included ownership of long-range planning, capital allocation projects and the financial aspects of Mergers & Acquisitions/Business Development. From January 2000 through April 2008, Ms. Sullivan served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. Ms. Sullivan is on the board of directors of BiomX Inc. (PHGE) and Solid Biosciences LLC (SLDB) where she has chaired the Audit Committee since 2015. Ms. Sullivan holds a B.S. in Accounting from Suffolk University and a M.S. in Taxation from Bentley College. Ms. Sullivan was a Certified Public Accountant for over 20 years.